Top Biopharma Deal July 2021: Arvinas – Pfizer ARV-471 PROTAC Protein Degrader for ER+/HER2- Breast Cancer
Top Biopharma Partnership by Upfront Cash and Equity
July 2021
Arvinas development and commercialization deal with Pfizer for ARV-471
Announced: July 22, 2021
Total Deal Value: $2,400M
Upfront Cash: $650M
Upfront Equity: $350M (3.5M new common, 30% prem.)
Option Payments: n/a
Milestones: $1,400M ($400M Reg. and $1B Sales)
Cost and Profit Split: 50%
The Asset:
Phase II ARV-471 oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor protein degrader for the treatment of estrogen receptor (ER) positive or human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) locally advanced or metastatic breast cancer.
Deal Structure:
Development and Commercial License
Partnership Features:
Equal cost and profit split for development and commercialization.
The Details:
- Arvinas granted Pfizer exclusive, worldwide rights to develop and commercialize ARV-471 for ER+/HER2- breast cancer.
- Arvinas and Pfizer will split development and commercialization costs and profits equally.
- Arvinas will receive $650M in upfront cash and Pfizer will receive approximately 3.5M newly issued shares of Arvinas common stock at a 30% premium valued at $350M, which represents an approx. 7% equity ownership stake by Pfizer. Additionally, Arnivas is eligible for up to $400M in approval milestones and up to $1B in commercial milestones.
Last Month:
The Deal of the Month for June 2021 was iTeos and GSK’s TIGIT deal with $625M up front for EOS-448. Read about it here.
DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms. We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.
Want data for your analysis? Want us to do it? Subscribers get both.
Schedule your demo of the DealForma database to see how we help you get better reports done faster.
25,544
Deal Profiles
15,147
Funding Rounds
28,034
Company Profiles
17,936
Product Profiles
119K+
Clinical Trials
3,982
Business Developers
Specifically for Biotech, Pharma, Device, and Diagnostics
Get more done.
Stop cleaning data or getting lost in legacy databases. We built DealForma to help you be better and faster at business research. Schedule your customized demo to see how DealForma helps you impress your boss and sign-off early.
More Research by DealForma
Biopharma Deal of the Month: Vir – GSK for VIR-2482 and mAbs for Influenza
Vir Biotechnology and GSK expanded their partnership with a new deal to develop VIR-2482 and mAbs for influenza. This was the largest upfront cash and equity for a partnership signed in Feb. 2021.
Biotech and Pharma M&A in 2020
Biotech and pharma M&A total deal values slumped in 2020, despite an active year in life sciences dealmaking, with no big standout biopharma deals until late in the second half of the year. We look at the extensive DealForma database to see how life sciences M&A activity shaped up in 2020 in more detail.
Life Sciences M&A Tops $240 Billion in 2019
This article is a sample from the DealForma Annual Deal Trends Report provided to database subscribers. Data for this analysis was compiled using the DealForma biopharma deals database. We applied initial filters for mergers and acquisitions, therapeutic areas, asset...
Cancer Cell Therapy M&A
Over the last three years, there have been eight M&A deals for companies developing advanced first generation and next gen cancer cell therapies. Six of them have been completed to date.
Gene Therapy Deals, M&A, and Venture Funding
We looked at 10 years of gene therapy deals, M&A, venture funding, and academic partnerships for an article by John Carroll at Endpoints News.
Reverse Mergers in Biopharma
Biotech reverse mergers have been an alternate way for private biotechnology companies to gain a public listing. Here’s a quick table of over 10 years of deals.
Biopharma Partnering Sets Records in Q1 2019 after a Strong 2018
2019 biopharma dealmaking started with a bang as the first quarter saw global biotech and pharma partnering deal values hit $38 billion in 282 deals.
Top 10 Venture Round Investors in Cancer Therapeutics
Celgene was among the top investors in cancer biotech companies. This is a look at the top 10 since 2010.
Life Sciences M&A Starts with a Bang in 2019 after Rebounding in 2018
Life Sciences M&A started with a bang in 2019 with one of the biggest deals to date – Bristol-Myers Squibb will acquire Celgene for $74 billion. We mined DealForma’s extensive database for historical M&A trends in biopharma, medical devices, and diagnostics to get an idea of what might lie ahead in 2019.
Oncology Partnering Deal Trends: Early Stage Deals Dominate with Highest Potential Deal Values
Innovative biotech companies are in a stronger position today as far as the value of their assets. We look at oncology deal payments by stage at signing.
You met on Zoom. Now it's Deal Time.
With thousands of company profiles and a decade of deals specifically in biopharma and medtech, you'll take the guesswork out of deal comps. Schedule your customized demo to see how DealForma helps you win that term sheet with better data.